United Therapeutics Corporation (NASDAQ:UTHR) is the 1st fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 59.6%. This number is based on the average estimate of 8 brokerage analyst(s).
Acorda Therapeutics Inc. (NASDAQ:ACOR) is the 2nd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 29.0%. This number is based on the average estimate of 3 brokerage analyst(s).
Celgene Corporation (NASDAQ:CELG) is the 3rd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 22.9%. This number is based on the average estimate of 16 brokerage analyst(s).
ShangPharma Corp (ADR) (NYSE:SHP) is the 4th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 19.7%. This number is based on the average estimate of 3 brokerage analyst(s). PAREXEL
International Corporation (NASDAQ:PRXL) is the 5th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 17.4%. This number is based on the average estimate of 6 brokerage analyst(s).
Pharmaceutical Product Development, Inc. (NASDAQ:PPDI) is the 6th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 17.0%. This number is based on the average estimate of 8 brokerage analyst(s).
Covance Inc. (NYSE:CVD) is the 7th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 16.5%. This number is based on the average estimate of 8 brokerage analyst(s).
Gilead Sciences, Inc. (NASDAQ:GILD) is the 8th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 15.4%. This number is based on the average estimate of 13 brokerage analyst(s).
Meridian Bioscience, Inc. (NASDAQ:VIVO) is the 9th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 14.8%. This number is based on the average estimate of 4 brokerage analyst(s).
WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) is the 10th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 14.2%. This number is based on the average estimate of 8 brokerage analyst(s).
